Mayo Clinic researchers studied the outcomes of 483 high-risk patients treated for COVID-19 with a five-day oral regimen of nirmatrelvir and ritonavir, together marketed as Paxlovid. Only a handful developed COVID-19 rebound symptoms, and the researchers say more studies are needed to determine why.
Overall, the treatment benefited everyone in the study. All recovered, including the patients who developed rebound symptoms, which were generally mild. The findings appear in the journalClinical Infectious Diseases.
"We found that rebound phenomenon was uncommon in this group of patients," says senior author Aditya Shah, M.B.B.S., a Mayo Clinic infectious diseases physician and researcher. "The four individuals who experienced rebound (symptoms) represent only 0.8% of the group, and all of them recovered quickly without additional COVID-directed therapy."
Most of the patients had been vaccinated, and many had received booster vaccinations. The median age was 63. While these patients were high-risk for COVID, none was immunocompromised. Only two patients were admitted to the hospital, and it was for reasons other than COVID-19.
The study zeros in on four patients with rebound symptoms:
Why did some rebound?
Researchers think one explanation could be that a replication of the SARS-CoV-2 virus -- the virus that causes COVID-19 -- may have triggered a secondary immune response that showed up as mild COVID-19 symptoms. They suggest further prospective studies could answer the question. They also note that all four patients with rebound symptoms had many serious health problems known as comorbidities -- a factor shown to complicate recoveries. And all four patients had been vaccinated more than 90 days before becoming infected with COVID-19.
Mayo Clinic funded the study. Others on the study team include first author Nischal Ranganath M.D., Ph.D.; John O'Horo, M.D.; Douglas Challener, M.D.; Sidna Tulledge-Scheitel, M.D.; Marsha Pike, D.N.P.; Michael O'Brien; and Raymund Razonable, M.D. -- all of Mayo Clinic.
Story Source:
Materialsprovided byMayo Clinic. Original written by Robert Nellis.注:内容可能edited for style and length.
Journal Reference:
Cite This Page: